Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

November 2020

New York, NY – November 04, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 2020 Stifel Virtual Healthcare Conference at 8:40 A.M. EST on November 16, 2020.   To view this virtual presentation live, register for the event here.   Links